Legal Advantage Investments Inc. Sells 200 Shares of AstraZeneca PLC (NASDAQ:AZN)

Legal Advantage Investments Inc. cut its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.8% during the fourth quarter, HoldingsChannel reports. The firm owned 3,950 shares of the company’s stock after selling 200 shares during the period. Legal Advantage Investments Inc.’s holdings in AstraZeneca were worth $259,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. McClarren Financial Advisors Inc. lifted its position in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the period. Capital Performance Advisors LLP bought a new stake in AstraZeneca during the 3rd quarter valued at $28,000. Ashton Thomas Securities LLC bought a new position in shares of AstraZeneca in the 3rd quarter worth $45,000. Hollencrest Capital Management grew its stake in AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after purchasing an additional 192 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in AstraZeneca by 2,618.5% in the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after purchasing an additional 707 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZN opened at $66.60 on Tuesday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $206.53 billion, a PE ratio of 31.87, a P/E/G ratio of 1.04 and a beta of 0.46. The firm has a 50 day moving average of $66.11 and a two-hundred day moving average of $74.46.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 EPS. On average, analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current year.

Analysts Set New Price Targets

AZN has been the topic of a number of analyst reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.